-
Have you heard the exciting announcement about the official approval of Yutrepia?
🎉 Big News for the PH Community! 🎉
The FDA has officially approved Yutrepia, an inhaled dry powder form of treprostinil, for treating PAH and PH-ILD — and this is huge for our community!
And our PH News team did an exceptional job of capturing the news in their article below.
In the article titled, “FDA approves Yutrepia, inhaled treprostinil, for PAH and PH-ILD.”
Here are a few key takeaways:
- Yutrepia can now be marketed in the U.S. after previously holding tentative approval.
- It helps improve exercise capacity and eases symptoms by opening blood vessels in the lungs.
- Designed with portability, ease-of-use, and personalization in mind.
This approval brings new hope, better options, and more support for our PH and PH-ILD community!
I’m certainly excited on a personal note, too, because my PH team plans to start me on this treatment next month!
What are your thoughts about this new inhaled treatment? Is anyone else considering this treatment option? Have you heard of Yutrepia before this mention? If so, where or from whom? Let’s keep this conversation going!
Log in to reply.